Designed for rapid—and prolonged—action
Unique, patented Ferr-Ease™* provides dual-iron absorption. In anemic patients, the rate of iron absorption increases significantly within minutes of administration.1 Because intestinal enterocytes can only absorb iron when it is in the ferrous state,2 the ferrous gluconate in Ferr-Ease is in the system to respond to this immediate need. Carbonyl iron allows gentle and prolonged solubilization and absorption, since the conversion of particulate carbonyl iron to soluble ionized iron is determined by the rate of gastric acid production.3
Designed for excellent tolerability
Ferrous gluconate and carbonyl iron share a profile of tolerability and safety. Ferrous gluconate is a good partner for carbonyl iron because it is associated with fewer side effects than other ferrous salts.4
Designed to make iron therapy more pleasant for patients
Ferralet® 90 addresses traditional drawbacks of iron therapy. The gentle stool softener docusate sodium eases constipation in iron-sensitive women. The vanilla scent improves the taste and smell normally associated with iron therapy. And, with a formulation free of lactose and gluten, many dietary concerns are met.
Important Safety Information
WARNING: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. KEEP THIS PRODUCT OUT OF THE REACH OF CHILDREN. In case of accidental overdose, call a doctor or poison control center immediately.
Warning
Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where vitamin B12 is deficient.
Precautions
Administration of Drug- General: Take 2 hours after meals. Do not exceed recommended dose. Discontinue use if symptoms of intolerance appear. The type of anemia and underlying cause or causes should be determined before starting therapy with Ferralet® 90 tablets. Ensure Hgb, Hct, reticulocyte count are determined before starting therapy and periodically thereafter during prolonged treatment. Periodically review therapy to determine if it needs to be continued without change or if a dose change is indicated. This product contains FD&C Yellow No. 5 (tartrazine) which may cause allergic type reactions (including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.
- Folic Acid: Folic acid in doses above 0.1 mg daily may obscure pernicious anemia in that hematologic remission can occur while neurological manifestations remain progressive. Pernicious anemia should be excluded before using these products since folic acid may mask the symptoms of pernicious anemia.
- Pediatric Use: Safety and effectiveness in pediatric patients have not been established.
- Geriatric Use: Dosing for elderly patients should be cautious. Due to the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy, dosing should start at the lower end of the dosing range.
This material is intended to provide basic information. Patients should discuss all medical advice, diagnosis, and treatment with their healthcare provider.
Please see full Prescribing Information
* US Patent no. 6,521,247 B1
- Rimon E, Kagansky N, Kagansky M, Mechnick L, Mashiah T, Namir M, Levy S. Are we giving too much iron? Low-dose iron therapy is effective in octogenarians. Am J Med. 2005 Oct;118(10):1142-7.
- Donovan A, Roy CN, Andrews NC. The ins and outs of iron homeostasis. Physiology (Bethesda). 2006 Apr;21:115-23.
- Huebers HA, Brittenham GM, Csiba E, Finch CA. Absorption of carbonyl iron. J Lab Clin Med. 1986 Nov;108(5):473-8.
- Shah A. Iron deficiency anemia--Part III. Indian J Med Sci. 2004 May;58(5):214-6.
